REVOLUTION Medicines Inc

5.10.2026 г., 23:50 ч. UTC

Revolution Medicines Inc saw a modest increase in after-market trading, continuing a trend of six consecutive daily gains while remaining above its 20-day moving average.

1.10.2026 г., 20:07 ч. UTC

Revolution Medicines Inc's shares are advancing as CEO Mark Goldsmith's independence strategy gains attention, positioning the company for growth in cancer treatments.

30.09.2026 г., 23:30 ч. UTC

Revolution Medicines Inc is trading modestly higher in after-market hours, supported by broader market gains and positive U.S. GDP and inflation data.

29.09.2026 г., 22:10 ч. UTC

Revolution Medicines Inc experienced a modest decline during after-market hours on Tuesday, continuing to trade within its one-month range.

28.09.2026 г., 19:51 ч. UTC

Revolution Medicines shares fell sharply despite Bank of America raising its price target to $265 and Brookline projecting $1.7 billion in revenue by 2027.

25.09.2026 г., 20:02 ч. UTC

Revolution Medicines Inc shares are advancing notably, supported by increased trading volume and positive trends in the biotechnology sector since Thursday's close.

24.09.2026 г., 23:01 ч. UTC

Revolution Medicines Inc is trading modestly lower in after-market hours, following a broader market decline and unusual volatility, remaining below its 20-day moving average.

23.09.2026 г., 20:07 ч. UTC

Revolution Medicines Inc. shares fell sharply despite receiving FDA Breakthrough Therapy Designation for RASONQUE, amid broader market declines and rising U.S. Treasury yields.

21.09.2026 г., 20:02 ч. UTC

Revolution Medicines Inc shares are trading higher as BofA Securities reaffirms a Buy rating and raises the price target to $265.

18.09.2026 г., 20:02 ч. UTC

Revolution Medicines Inc shares fell sharply, continuing a decline since Thursday's close, amid broader weakness in the Containers & Packaging sector and high trading volume.

17.09.2026 г., 19:36 ч. UTC

Revolution Medicines Inc shares fell modestly after reaching a notable high earlier, currently trading below the 20-day moving average amid broader market weakness.

16.09.2026 г., 20:06 ч. UTC

Revolution Medicines Inc shares fell sharply, reversing recent gains, with unusually high trading volume reflecting increased market activity.

15.09.2026 г., 23:11 ч. UTC

Revolution Medicines shares declined in after-market trading, remaining below the 20-day moving average amid broader market concerns over inflation and rising U.S. crude inventories.

11.09.2026 г., 20:08 ч. UTC

Revolution Medicines Inc shares are higher during Friday's session, despite earlier pulling back from an intraday high. No specific news was identified for the movement.

3.09.2026 г., 19:16 ч. UTC

Revolution Medicines Inc shares are higher after positive Phase 1/2 trial results for RASONQUE in advanced RAS mutant non-small cell lung cancer were published.

2.09.2026 г., 23:51 ч. UTC

Revolution Medicines shares rise in after-market trading following positive Phase 1/2 data on RASONQUE for advanced RAS mutant non-small cell lung cancer.

1.09.2026 г., 23:06 ч. UTC

Revolution Medicines Inc shares are higher in after-market trading, maintaining a stable performance since Tuesday's close despite earlier session volatility.

31.08.2026 г., 20:07 ч. UTC

Revolution Medicines Inc shares are lower amid broader market pressures and concerns from the Jackson Hole Economic Symposium regarding inflation and monetary policy tightening.

28.08.2026 г., 20:02 ч. UTC

Revolution Medicines shares are lower amid significant selling pressure, despite recent price target increases by UBS and others for its drug RASONQUE.

27.08.2026 г., 23:02 ч. UTC

Revolution Medicines Inc shares are higher in after-market trading following FDA approval of RASONQUE for metastatic pancreatic cancer, discussed during an August 26 conference call.

26.08.2026 г., 23:21 ч. UTC

Oppenheimer raised Revolution Medicines' price target to $260, citing FDA approval of RASONQUE for advanced pancreatic cancer, as shares trade higher in after-market hours.

25.08.2026 г., 20:07 ч. UTC

Revolution Medicines Inc received a "Moderate Buy" rating from brokerages. Needham raised its price target to $240, while shares are trading roughly flat.

24.08.2026 г., 20:06 ч. UTC

Revolution Medicines Inc shares are higher today, recovering from an earlier low. The stock has gained since Friday's close amid rising oil prices.

21.08.2026 г., 19:46 ч. UTC

Revolution Medicines shares are lower today as Bernstein raised its price target to $179, continuing a trend of three consecutive daily declines.

20.08.2026 г., 23:26 ч. UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

19.08.2026 г., 19:46 ч. UTC

Revolution Medicines Inc shares are lower Wednesday, pulling back after reaching a session high. The stock has declined since Tuesday's close.

17.08.2026 г., 19:51 ч. UTC

Revolution Medicines shares are higher since Friday's close as Baker Bros boosts its stake to 11.4 million shares, valued at $2 billion.

13.08.2026 г., 19:36 ч. UTC

Revolution Medicines Inc shares are lower, reaching a session low earlier. This decline follows a cumulative drop since Wednesday's close.

12.08.2026 г., 23:16 ч. UTC

Revolution Medicines shares declined in after-market trading, despite earlier gains. The Consumer Price Index report showed a modest rise in consumer prices today.

11.08.2026 г., 19:36 ч. UTC

Revolution Medicines Inc is trading lower as broader geopolitical tensions and upcoming U.S. inflation reports weigh on market sentiment.